230 related articles for article (PubMed ID: 27043267)
1. Identification of N-phenyl-2-(N-phenylphenylsulfonamido)acetamides as new RORγ inverse agonists: Virtual screening, structure-based optimization, and biological evaluation.
Song Y; Xue X; Wu X; Wang R; Xing Y; Yan W; Zhou Y; Qian CN; Zhang Y; Xu Y
Eur J Med Chem; 2016 Jun; 116():13-26. PubMed ID: 27043267
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide derivatives as new RORγ inhibitors using virtual screening, synthesis and biological evaluation.
Zhang Y; Xue X; Jin X; Song Y; Li J; Luo X; Song M; Yan W; Song H; Xu Y
Eur J Med Chem; 2014 May; 78():431-41. PubMed ID: 24704616
[TBL] [Abstract][Full Text] [Related]
3. Discovery and structural optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-ones as RORc inverse agonists.
Wu XS; Wang R; Xing YL; Xue XQ; Zhang Y; Lu YZ; Song Y; Luo XY; Wu C; Zhou YL; Jiang JQ; Xu Y
Acta Pharmacol Sin; 2016 Nov; 37(11):1516-1524. PubMed ID: 27374490
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel pyrazole-containing benzamides as potent RORγ inverse agonists.
Wang T; Banerjee D; Bohnert T; Chao J; Enyedy I; Fontenot J; Guertin K; Jones H; Lin EY; Marcotte D; Talreja T; Van Vloten K
Bioorg Med Chem Lett; 2015 Aug; 25(15):2985-90. PubMed ID: 26048789
[TBL] [Abstract][Full Text] [Related]
5. Potent and Orally Bioavailable Inverse Agonists of RORγt Resulting from Structure-Based Design.
Narjes F; Xue Y; von Berg S; Malmberg J; Llinas A; Olsson RI; Jirholt J; Grindebacke H; Leffler A; Hossain N; Lepistö M; Thunberg L; Leek H; Aagaard A; McPheat J; Hansson EL; Bäck E; Tångefjord S; Chen R; Xiong Y; Hongbin G; Hansson TG
J Med Chem; 2018 Sep; 61(17):7796-7813. PubMed ID: 30095900
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 1-{4-[3-fluoro-4-((3s,6r)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmethyl)-phenyl]-piperazin-1-yl}-ethanone (GNE-3500): a potent, selective, and orally bioavailable retinoic acid receptor-related orphan receptor C (RORc or RORγ) inverse agonist.
Fauber BP; René O; Deng Y; DeVoss J; Eidenschenk C; Everett C; Ganguli A; Gobbi A; Hawkins J; Johnson AR; La H; Lesch J; Lockey P; Norman M; Ouyang W; Summerhill S; Wong H
J Med Chem; 2015 Jul; 58(13):5308-22. PubMed ID: 26061388
[TBL] [Abstract][Full Text] [Related]
7. Structural determinant for inducing RORgamma specific inverse agonism triggered by a synthetic benzoxazinone ligand.
Marcotte DJ; Liu Y; Little K; Jones JH; Powell NA; Wildes CP; Silvian LF; Chodaparambil JV
BMC Struct Biol; 2016 Jun; 16(1):7. PubMed ID: 27246200
[TBL] [Abstract][Full Text] [Related]
8. Benzoxazepines Achieve Potent Suppression of IL-17 Release in Human T-Helper 17 (TH 17) Cells through an Induced-Fit Binding Mode to the Nuclear Receptor RORγ.
Olsson RI; Xue Y; von Berg S; Aagaard A; McPheat J; Hansson EL; Bernström J; Hansson P; Jirholt J; Grindebacke H; Leffler A; Chen R; Xiong Y; Ge H; Hansson TG; Narjes F
ChemMedChem; 2016 Jan; 11(2):207-16. PubMed ID: 26553345
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.
Zhang Y; Wu X; Xue X; Li C; Wang J; Wang R; Zhang C; Wang C; Shi Y; Zou L; Li Q; Huang Z; Hao X; Loomes K; Wu D; Chen HW; Xu J; Xu Y
J Med Chem; 2019 May; 62(9):4716-4730. PubMed ID: 30964293
[TBL] [Abstract][Full Text] [Related]
10. Identification and structure activity relationships of quinoline tertiary alcohol modulators of RORγt.
Kummer DA; Cummings MD; Abad M; Barbay J; Castro G; Wolin R; Kreutter KD; Maharoof U; Milligan C; Nishimura R; Pierce J; Schalk-Hihi C; Spurlino J; Urbanski M; Venkatesan H; Wang A; Woods C; Xue X; Edwards JP; Fourie AM; Leonard K
Bioorg Med Chem Lett; 2017 May; 27(9):2047-2057. PubMed ID: 28318945
[TBL] [Abstract][Full Text] [Related]
11. Discovery of biaryl carboxylamides as potent RORγ inverse agonists.
Chao J; Enyedy I; Van Vloten K; Marcotte D; Guertin K; Hutchings R; Powell N; Jones H; Bohnert T; Peng CC; Silvian L; Hong VS; Little K; Banerjee D; Peng L; Taveras A; Viney JL; Fontenot J
Bioorg Med Chem Lett; 2015 Aug; 25(15):2991-7. PubMed ID: 26048806
[TBL] [Abstract][Full Text] [Related]
12. Identification of N-sulfonyl-tetrahydroquinolines as RORc inverse agonists.
Fauber BP; Gobbi A; Savy P; Burton B; Deng Y; Everett C; La H; Johnson AR; Lockey P; Norman M; Wong H
Bioorg Med Chem Lett; 2015 Oct; 25(19):4109-13. PubMed ID: 26321361
[TBL] [Abstract][Full Text] [Related]
13. Discovery of biaryls as RORγ inverse agonists by using structure-based design.
Enyedy IJ; Powell NA; Caravella J; van Vloten K; Chao J; Banerjee D; Marcotte D; Silvian L; McKenzie A; Hong VS; Fontenot JD
Bioorg Med Chem Lett; 2016 May; 26(10):2459-2463. PubMed ID: 27080181
[TBL] [Abstract][Full Text] [Related]
14. Discovery of phenoxyindazoles and phenylthioindazoles as RORγ inverse agonists.
Ouvry G; Bouix-Peter C; Ciesielski F; Chantalat L; Christin O; Comino C; Duvert D; Feret C; Harris CS; Lamy L; Luzy AP; Musicki B; Orfila D; Pascau J; Parnet V; Perrin A; Pierre R; Polge G; Raffin C; Rival Y; Taquet N; Thoreau E; Hennequin LF
Bioorg Med Chem Lett; 2016 Dec; 26(23):5802-5808. PubMed ID: 27815118
[TBL] [Abstract][Full Text] [Related]
15. N-Arylsulfonyl Indolines as Retinoic Acid Receptor-Related Orphan Receptor γ (RORγ) Agonists.
Doebelin C; Patouret R; Garcia-Ordonez RD; Chang MR; Dharmarajan V; Kuruvilla DS; Novick SJ; Lin L; Cameron MD; Griffin PR; Kamenecka TM
ChemMedChem; 2016 Dec; 11(23):2607-2620. PubMed ID: 27879053
[TBL] [Abstract][Full Text] [Related]
16. Discovery and Characterization of CD12681, a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of Psoriasis.
Ouvry G; Atrux-Tallau N; Bihl F; Bondu A; Bouix-Peter C; Carlavan I; Christin O; Cuadrado MJ; Defoin-Platel C; Deret S; Duvert D; Feret C; Forissier M; Fournier JF; Froude D; Hacini-Rachinel F; Harris CS; Hervouet C; Huguet H; Lafitte G; Luzy AP; Musicki B; Orfila D; Ozello B; Pascau C; Pascau J; Parnet V; Peluchon G; Pierre R; Piwnica D; Raffin C; Rossio P; Spiesse D; Taquet N; Thoreau E; Vatinel R; Vial E; Hennequin LF
ChemMedChem; 2018 Feb; 13(4):321-337. PubMed ID: 29327456
[TBL] [Abstract][Full Text] [Related]
17. RORγ antagonists and inverse agonists: a patent review.
Bronner SM; Zbieg JR; Crawford JJ
Expert Opin Ther Pat; 2017 Jan; 27(1):101-112. PubMed ID: 27629281
[TBL] [Abstract][Full Text] [Related]
18. Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-γ (RORγ or RORc).
Fauber BP; Magnuson S
J Med Chem; 2014 Jul; 57(14):5871-92. PubMed ID: 24502334
[TBL] [Abstract][Full Text] [Related]
19. The cardenolides strophanthidin, digoxigenin and dihydroouabain act as activators of the human RORγ/RORγT receptors.
Karaś K; Sałkowska A; Walczak-Drzewiecka A; Ryba K; Dastych J; Bachorz RA; Ratajewski M
Toxicol Lett; 2018 Oct; 295():314-324. PubMed ID: 29981919
[TBL] [Abstract][Full Text] [Related]
20. Structural studies unravel the active conformation of apo RORγt nuclear receptor and a common inverse agonism of two diverse classes of RORγt inhibitors.
Li X; Anderson M; Collin D; Muegge I; Wan J; Brennan D; Kugler S; Terenzio D; Kennedy C; Lin S; Labadia ME; Cook B; Hughes R; Farrow NA
J Biol Chem; 2017 Jul; 292(28):11618-11630. PubMed ID: 28546429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
